Making pharmacogenetic testing a reality in a community pharmacy.

@article{OConnor2012MakingPT,
  title={Making pharmacogenetic testing a reality in a community pharmacy.},
  author={Shanna K. O’Connor and Stefanie P. Ferreri and Natasha M. Michaels and Rebecca W. Chater and Anthony J. Viera and Hawazin Faruki and Howard L. McLeod and Mary W. Roederer},
  journal={Journal of the American Pharmacists Association : JAPhA},
  year={2012},
  volume={52 6},
  pages={
          e259-65
        }
}
OBJECTIVE To provide information for community pharmacies considering implementation of a pharmacogenetic testing service. SETTING A single community pharmacy from a regional chain. PRACTICE DESCRIPTION Community pharmacists at the study site routinely provide pharmacy services including medication therapy management, immunizations, point-of-care testing, blood pressure monitoring, and diabetes education. The pharmacy is a training site for post-graduate year 1 and 2 community-pharmacy… 

Figures from this paper

Implementation of a pharmacogenomics service in a community pharmacy.

A pharmacogenomics service can be an extension of medication therapy management services in a community pharmacy, and Prescribers are receptive to having community pharmacists conduct pharmacogenomic testing, but reimbursement is a challenge.

Implementation of a Pharmacogenomic Testing Service through Community Pharmacy in the Netherlands: Results from an Early Service Evaluation

The aim of this work was to describe how best to implement PGx services within community pharmacy, considering potential barriers and enablers to service delivery and how to address them.

Expansion of pharmacogenomics into the community pharmacy: billing considerations.

Key legal, ethical and economic considerations for pharmacists interested in seeking reimbursement for pharmacogenomics-related services in the US are discussed.

Community pharmacists' experience with pharmacogenetic testing.

The provision of PGx services in a community pharmacy setting appears feasible, requiring little additional time from the pharmacist, and many patients seem interested in PGx testing.

Pharmacogenomics competencies in pharmacy practice: A blueprint for change.

Implementation of a pharmacogenetic management service for postmyocardial infarction care in a community pharmacy.

A multisite, proof-of-concept model where community pharmacists could engage patients and physicians to provide pharmacogenetic (PGt) testing and clinical decision support supports the involvement of the community pharmacist in making PGt-based recommendations.

Evaluation of a pharmacogenetic educational toolkit for community pharmacists.

Though the usability of the toolkit overall was below average, individual components were perceived as useful and more than 75% of pharmacists reported that they would use the tool kit components when offering testing, with the result summary sheet receiving the highest score.

Pharmacogenomics at the Point of Care: A Community Pharmacy Project in British Columbia

It is found that medication adjustments and dosing changes across the entire cohort added $24.15CAD per patient per year for those that required an adjustment, and pharmacogenomic services offered by pharmacists are ready for wide commercial implementation.

Integrating pharmacogenetic testing into primary care

  • S. Haga
  • Medicine
    Expert review of precision medicine and drug development
  • 2017
In this paper, the readiness of primary care practitioners are reviewed as well as strategies to address these barriers based on published research and ongoing activities on education and implementation of PGx testing.

References

SHOWING 1-10 OF 19 REFERENCES

Pharmacogenomics in a community pharmacy: ACT now.

Advances in knowledge and technology regarding pharmacogenomics coupled with the overwhelming access and use of a community pharmacist by patients provides a tremendous opportunity for community pharmacists to lay claim to the field of pharmacogenetics.

Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy.

An institutional review board-approved protocol for a clopidogrel pharmacogenetic program in a community pharmacy was developed to address feasibility and evaluate the pilot program.

Integrating pharmacogenomics into pharmacy practice via medication therapy management.

  • Susan M. Reiss
  • Medicine, Political Science
    Journal of the American Pharmacists Association : JAPhA
  • 2011
The pharmacy profession must define a process for the application of pharmacogenomic data into pharmacy clinical practice that is aligned with MTM service delivery, develop a viable business model for these practices, and encourage and direct the development of HIT solutions that support the pharmacist's role in this emerging field.

Integrating pharmacogenomics into pharmacy practice via medication therapy management

The pharmacy profession must define a process for the application of pharmacogenomic data into pharmacy clinical practice that is aligned with MTM service delivery, develop a viable business model for these practices, and encourage and direct the development of an effective infrastructure for this process.

Development and implementation of a pharmacist-managed clinical pharmacogenetics service.

  • K. CrewsS. Cross J. M. Hoffman
  • Medicine, Biology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
The successful implementation of this service highlights the leadership role that pharmacists can take in moving pharmacogenetics from research to patient care, and the program's success has depended on collaboration between the clinical laboratory and pharmacists.

Positioning and integrating medication therapy management.

Findings from medication therapy management "environmental scans" conducted from 2007 through 2010 suggest that a "channel of distribution" is emerging in which organizational relationships and cost efficiencies will be important considerations in the near term.

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement information contained in FDA approved drug labels and that with supporting knowledge, sufficient clinical data exists in University of Washington’s EMR systems to support 50% ofPGx knowledge contained in drug labels that could be expressed as rules.

HLA-B*5701 screening for hypersensitivity to abacavir.

In a study of over 1900 HIV-1-infected patients, HLA-B*5701 screening prior to administering an abacavir-containing regimen, with avoidance of the antiretroviral abacvir in HLA_B* 5701-positive patients, was shown to be a highly effective pharmacogenetic test.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy

Evidence is provided for the use of CYPC19 genotype–directed antiplatelet therapy in patients with acute coronary syndromes who are receiving clopidogrel, particularly among those undergoing percutaneous coronary intervention (PCI).

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites, resulting in reduced